Clinical data
Trade names Atelec (アテレック), Cilacar
AHFS/ International Drug Names
ATC code C08CA14 (WHO)
CAS Number 132203-70-4
PubChem (CID) 5282138
ChemSpider 4445338
KEGG D01173
ECHA InfoCard 100.162.338
Chemical and physical data
Formula C27H28N2O7
Molar mass 492.52 g/mol
3D model (Jmol) Interactive image

Cilnidipine (INN) is a calcium channel blocker. Cilnidipine is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists.

Cilnidipine is approved for use in Japan, China,India, Korea and some European countries.

Medical uses

Cilnidipine due to its blocking action at N-type and L type calcium channel dilates both arterioles and venules as a result the pressure in the capillary bed is reduced. It is used for hypertension management.

Adverse effects

Peripheral edema a common side effect of the use of amlodipine was found to be reduced when patients were shifted to cilnidipine.

Clinical Benefits

Cilnidipine has enhanced lipophilicity leading to prolonged antihypertensive effect correlated with occupancy of the binding site. In 24-hour clinical assessment, once-daily administration of cilnidipine produced blood pressuree reduction for 24-hour period. The inhibitory effect on the N-type Ca2+ channel may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia.

As catecholamines induce platelet activation via α2-receptor on platelet membrane, decrease in norepinephrine level by cilnidipine causes attenuation of platelet activation.

Brand names

In Bangladesh it is marketed by The ACME Laboratories Ltd. under the brand name DUOCARD, available as both 5 mg & 10 mg and Opsonin Pharma Ltd. under the brand name CILDIP and is available in the two strengths 5 mg & 10 mg Tablet. In India it is marketed by JBCPL under the brand name CILACAR and is available in the three strengths, 5 mg, 10 mg, 20 mg & combinations also availlable CILACAR T, CILACAR T80, CILACAR M, CILACAR C12.5, CILACAR C6.25, CILACAR TC12.5, CILACAR TC6.25. In Japan it is marketed BY Ajinomoto Pharmaceuticals Co., Ltd.under the brand name Atelec. In usa it is available in different brands whose central ingredients are CILNIDIPINE like-ATELEC & CILACAR (Ref: 20)


    This article is issued from Wikipedia - version of the 11/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.